SCHEMBL2567218

SCHEMBL2567218

O=C1Cc2c(nc(Oc3ccc(F)cc3)n(-c3ccc(OCC(F)(F)F)cc3)c2=O)N1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 1/20 0.37
SLC5A1 P13866 2/20 0.36
FADS1 O60427 1/20 0.35
PIK3CD O00329 2/20 0.35
PIK3CB P42338 2/20 0.35
PIK3CG P48736 2/20 0.35
PIK3CA P42336 1/20 0.35
KCNH2 Q12809 3/20 0.35
HRH3 Q9Y5N1 3/20 0.35
LIPE Q05469 3/20 0.35
SCN9A Q15858 1/20 0.34
PIM1 P11309 1/20 0.34
PDE10A Q9Y233 2/20 0.33
AXL P30530 1/20 0.33
MERTK Q12866 1/20 0.33
SCN8A Q9UQD0 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005623 0.92 AXL (0.34) UGCGKCNH2HRH3SCN9APIM1
SCHEMBL2567232 0.92 KCNH2 (0.37) FADS1PIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL2561172 0.91 POLB (0.40) FADS1PIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL2568408 0.91 SLC5A1 (0.36) SLC5A1FADS1PIK3CDPIK3CBPIK3CG
SCHEMBL2564954 0.91 FADS1 (0.37) UGCGSLC5A1FADS1PIK3CDPIK3CB
SCHEMBL2568067 0.87 FADS1 (0.37) UGCGSLC5A1FADS1PIK3CDPIK3CB
SCHEMBL2564400 0.86 FADS1 (0.35) UGCGSLC5A1FADS1PIK3CDPIK3CB
SCHEMBL2564033 0.86 FADS1 (0.35) UGCGSLC5A1FADS1PIK3CDPIK3CB
SCHEMBL2564084 0.86 FADS1 (0.35) UGCGSLC5A1FADS1PIK3CDPIK3CB
SCHEMBL2563240 0.85 ALDH1A1 (0.38) UGCGSLC5A1FADS1PIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382218-A1 DELTA-5-DESATURASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-11-02 EP disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190747-A1 Fused ring compound and use thereof CYP46A1, LTB4R2, PTGES UGCG 1283/4885SLC5A1 658/4885FADS1 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.